TaiMed Biologics earned FDA approval for its new HIV drug Trogarzo March 6.
Here are three things to know.
1. Trogarzo is an antiretroviral medication for adult patients with HIV who do not respond to other HIV therapies on the market.
2. Clinicians administer the intravenous drug to a patient once every two weeks.
3. The drug should be used in combination with other antiretroviral medications.
"While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug-resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death," said Jeff Murray, MD, deputy director of the division of antiviral products in the FDA's Center for Drug Evaluation and Research. "Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options."